文献速递消化道肿瘤与早癌消化内镜食管胃疾病与幽门螺杆菌

中国2021-2035年全国胃癌预防:效果、可负担性与成本效果优化的决策分析

Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation.
PubMed 文献 · Gut · 2022-07-28

该决策分析以1951-1980年出生的中国男女队列为基础,假设根除幽门螺杆菌及不同频率内镜筛查等策略,用马尔可夫模型预测2021-2035年胃癌新发病例与死亡数、资源需求和QALYs。结果显示根除幽门螺杆菌为节省成本策略,一般人群年度筛查虽占优但每获得QALY成本超过7万元,高风险人群按个人风险定制筛查频率可减少内镜资源。

要点

  • 根除幽门螺杆菌相对现状为节省成本策略。
  • 一般人群年度筛查占优,但每获得QALY成本超过7万元。

核心结论

  • 研究结果为未来决策和投资提供重要依据,强调中国将胃癌预防纳入国家健康计划的必要性和可行性。

研究设计与样本

  • 基于1951-1980年出生的中国男女队列的决策分析,假设根除幽门螺杆菌及内镜筛查(一次性、每年、每2年、每3年或按个人风险分层)等不同预防策略,通过文献检索获取最新数据并构建马尔可夫模型,预测2021-2035年胃癌新发病例和死亡数、资源需求及质量调整生命年(QALYs),并考察一般人群(全人群)和靶向(高风险人群)预防的影响。

主要发现

  • 相对现状,根除幽门螺杆菌为节省成本策略。
  • 一般年度筛查优于其他筛查策略,但与根除幽门螺杆菌相比,每获得QALY成本超过7万元(支付意愿阈值)。
  • 在内镜策略中,靶向筛查较一般筛查每获得QALY相对现状的成本低44%-49%。
  • 在高风险人群中,按个人风险定制筛查频率较每2年筛查减少内镜相关资源22%,较每年筛查减少55%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To project future trajectories of the gastric cancer (GC) burden in China under different scenarios of GC prevention and identify strategies to improve affordability and cost-effectiveness. DESIGN: Using a cohort of Chinese men and women born during 1951-1980, we assumed that different prevention strategies were conducted, including eradication of Helicobacter pylori (Hp) and endoscopy screening (one-time, annual, biennial, triennial or stratified according to personal risk). We performed a literature search to identify up-to-date data and populate a Markov model to project the number of new GC cases and deaths during 2021-2035, as well as resource requirements and quality-adjusted life-years (QALYs). We examined the impacts of general (among the whole population) and targeted (high-risk population) prevention. RESULTS: During 2021-2035, 10.0 million new GC cases and 5.6 million GC deaths would occur, with 7.6%-35.5% and 6.9%-44.5%, respectively, being avoidable through various prevention strategies. Relative to the status quo, Hp eradication was a cost-saving strategy. General annual screening dominated other screening strategies, but cost more than CNY 70 000 per QALY gained (willingness-to-pay) compared with Hp eradication. Among endoscopy strategies, targeted screening resulted in 44%-49% lower cost per QALY gained over the status quo than general screening. Among high-risk population, tailoring the screening frequency according to personal risk could reduce endoscopy-related resources by 22% compared with biennial screening and by 55% compared with annual screening, CONCLUSION: Our findings provide important input for future decision-making and investment, highlighting the need and feasibility for China to include GC prevention in its national health plans.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang Z, Han W, Xue F, et al. Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut. 2022. PMID: 35902213. doi:10.1136/gutjnl-2021-325948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。